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ABSTRACT 
Although an immune response to tumors may be generated using vaccines, so far, this 
approach has only shown minimal clinical success. This is attributed to the tendency of 
cancer to escape immune surveillance via multiple immune suppressive mechanisms. 
Successful cancer immunotherapy requires targeting these inhibitory mechanisms along 
with enhancement of antigen-specific immune responses to promote sustained tumor-
specific immunity. 
Here we evaluated the effect of indoximod, an inhibitor of the immunosuppressive 
indoleamine-(2,3)-dioxygenase (IDO) pathway, on antitumor efficacy of anti-OX40 
agonist in the context of vaccine in the IDO- TC-1 tumor model. We demonstrate that 
although the addition of anti-OX40 to the vaccine moderately enhances therapeutic 
efficacy, incorporation of indoximod into this treatment leads to enhanced tumor 
regression and cure of established tumors in 60% of treated mice. We show that the 
mechanisms by which the IDO inhibitor leads to this therapeutic potency include (i) an 
increment of vaccine-induced tumor-infiltrating effector T cells that is facilitated by anti-
OX40, and (ii) a decrease of IDO enzyme activity produced by non-tumor cells within the 
tumor microenvironment that results in enhancement of the specificity and the 
functionality of vaccine-induced effector T cells.  
Our findings suggest a translatable strategy to enhance the overall efficacy of cancer 
immunotherapy.  
 
 
Introduction  
 Improved cancer immunotherapy strategies would both evoke an immune 
response and resist tumor-driven immunosuppression. Successful immunotherapy 
depends on breaking tumor-mediated immune tolerance such that the immune system 
can be modulated to deliver T cells that could recognize and eradicate tumors. Induction 
of immune response against tumors is an efficient method to educate T cells with tumor 
antigens; however, suppressive mechanisms within the tumor microenvironment weaken 
the effector immune response. Thus, mitigating the immunosuppression while 
concurrently augmenting vaccine-induced antigen-specific T cells could improve the 
overall potency of cancer immunotherapy.  
Favorable outcomes follow increased number of tumor-specific effector T cells 
within the tumor environment [1-3]. To generate strong and long-lasting anti-cancer 
immune response upon antigen recognition, an engagement of secondary costimulatory 
receptors is often employed in combinational immune therapeutic studies [4-8]. 
A member of the tumor necrosis factor receptor (TNFR) superfamily, OX40 (CD134) is a 
costimulatory molecule [9] that is currently in clinical trials [10]. The OX40 receptor is 
inducible on activated T cells [11-15] and its engagement with cognate ligand or 
agonistic antibody enhances T-cell proliferation, cytokine production, survival and 
memory development [16, 17]. In animal models, anti-OX40 has shown favorable 
antitumor activities and in autoimmune models increases the severity of disease [18-23].  
In addition to augmenting the effector arm of the immune system, extensive studies have 
been devoted to immune tolerance and tumor-mediated immunosuppressive 
mechanisms, which render effector T cells ineffective in clearing malignant cells [24-26]. 
Tumor-mediated immune suppression includes inhibitory mechanisms elicited by tumor 
cells directly (co-inhibitory receptor/ligand interactions, secretion of inhibitory cytokines 
and other molecules) or indirectly (mechanisms based on tumor-recruited suppressive 
immune cells). We believe that targeting the indirect mechanisms would have wide 
application and that such a strategy could be used for immune therapy of a broad 
spectrum of tumors, regardless of their expression of specific molecules. 
One of the protective mechanisms is production of indoleamine-(2,3)-dioxygenase (IDO).  
IDO is produced not only by some tumors but also by inhibitory immune cells such as 
suppressive dendritic cells and monocyte-derived macrophages [27, 28]. In fact, IDO 
expression within the tumor microenvironment and tumor draining lymph nodes 
correlates with poor cancer prognosis [29-32]. IDO enzymatic activity potentiates 
tryptophan degradation, causing cell-cycle arrest and induction of anergy in effector T 
cells. Toxic tryptophan catabolites may lead to apoptosis of T cells and induction of 
regulatory T cells (Tregs) [33-38]. Accordingly, inhibition of the IDO pathway increases 
antitumor responses in murine models [27, 33, 38-40]. One of the relatively well 
characterized IDO pathway inhibitors is indoximod (1-methyl-D-tryptophan) [27, 39, 40].  
  We and others have previously demonstrated that successful cancer 
immunotherapy requires simultaneous targeting of both effector and suppressor arms of 
the immune system [41-45]. Since OX40 leads to increased INF expression in the 
periphery and within the tumor microenvironment [16, 17] and INF promotes the 
induction of IDO, we hypothesized that OX40 based antitumor immunotherapy could be 
improved by reducing immune suppression through inhibition of IDO. We therefore 
evaluated the therapeutic efficacy and immune mechanisms of treatment combining anti-
OX40Ab with indoximod in a vaccine setting in mice with established tumors. To test the 
effect of IDO inhibition on the immune component of the tumor microenvironment, we 
tested the combination in an IDO- tumor model, TC-1.  We demonstrate that this 
treatment is therapeutically potent and discuss immune mechanisms that explain the 
role of each component within the combination. Here, we provide evidence that 
simultaneous targeting of the effector arm with anti-OX40 and the suppressor arm of 
immune system with an IDO inhibitor, indoximod, produces a synergistic effect on the 
tumor immune response resulting in the enhancement of vaccine potency and in tumor 
eradication.  Considering that, on average, more than half of human tumors are IDO- 
[46], we believe that this treatment strategy is promising, can be applied to a wide range 
of tumors (including IDO–  tumors), and can improve the efficacy of cancer treatment.  
 
  
Material and Methods 
Mice and cell lines 
C57BL/6 female mice (6-8 weeks old, The Jackson Laboratory, Bar Harbor, ME) were 
housed in pathogen free environment. All procedures were carried out with approved 
Augusta University institutional animal protocols and NIH guidelines.  
TC-1 cell line, derived by co-transfection of human papilloma-virus strain 16 (HPV16) 
early proteins 6 and 7 (E6 and E7) and activated h-ras oncogene into primary lung 
epithelial cells, was obtained from American Type Culture Collection (Manassas, VA) 
and propagated in RPMI1640 supplemented with 10% FBS, penicillin and streptomycin 
(100 U/ml each), L-glutamine (2 mM) at 37°C with 5% CO2. Cells were maintained at a 
confluence of 70% to 80% and were always used from a passage number less than 10. 
These cells were tested routinely for absence of mycoplasma by using PCR at Georgia 
Cancer Center, Augusta University (Augusta, GA). All tests were negative. During the 
last one year, these cells were not re-authenticated.
 
This cell line was deliberately selected, as these tumor cells do not express IDO, 
allowing the study of the effect of the IDO inhibitor on the tumor microenvironment 
without interference from the direct effect on tumor cells. 
Vaccine and other reagents  
The CTL epitope from HPV16 E749–57 (9aa peptide, RAHYNIVTF, 100g/mouse) mixed 
with 13 amino acid synthetic nonnatural pan DR CD4+ T helper epitope (PADRE) [47] 
(13aa peptide, aK-Cha-VAAWTLKAAa, where a is D-alanine, and Cha is L-
cyclohexylalanine, 20g/mouse) (both from Celtek Bioscience, Franklin, TN) and QuilA 
adjuvant (20g/mouse) (Brenntag, Westbury, NY) was used as the model vaccine (that 
contains both CD8 and CD4 epitopes) in all studies [subcutaneous (s.c.) injections].  
indoximod (1-MT, Sigma-Aldrich) was provided in drinking water (freshly prepared every 
three days) at 2mg/mL concentration. Water was supplemented with low-fat sweetener 
to improve the water intake by mice. Once all the material was dissolved, the pH was 
adjusted to a range of 7-7.5 with 1N HCl and filtered through a 75mm filter unit. 
indoximod drinking solution was provided to mice in amber-colored or aluminum foil-
wrapped drinking bottle to protect from exposure to light. 
Agonist rat anti-mouse OX40 (clone OX86, rat IgG1) was provided by Medimmune 
(Cambridge, UK), and delivered by intraperitoneal (i.p.) injections at a dose of 1 mg/kg.  
 
Tumor implantation and treatment  
For both therapeutic and immunology experiments 7x104 TC-1 cells were inoculated s.c. 
into the right flank of the mice on day 0. Vaccine was given weekly s.c. starting on day 
10-12 after tumor implantation when tumor diameter reached 4-5 mm. For therapeutic 
experiments, vaccine was given weekly throughout the experiment. Anti-OX40 and 
indoximod treatments started on the same day with vaccination. Anti-OX40 was given 
twice a week for the entire duration of treatment. Similarly, indoximod was provided in 
drinking water until the end of the study. A total of eight groups of mice (n = 5) were 
utilized in these experiments, including non-treated, single and double agent-treated and 
vaccine/anti-OX40/indoximod treated groups. Tumor growth and survival was monitored. 
Tumors were measured every 3–4 days using digital calipers, and tumor volume was 
calculated using the formula V=(W2*L)/2, whereby V is the volume, L is the length 
(longer diameter) and W is width (shorter diameter). Mice were sacrificed when 
moribund or if tumor volume reached 1.5 cm3. For immunology experiments mice were 
treated similarly and were sacrificed six days after the second immunization. Tumors 
were harvested for analysis of tumor infiltrating cells and IDO activity. 
 
Profiling tumor-infiltrating immune cells   
Resected tumors were homogenized using GentleMACS Dissociator (Miltenyi Biotec, 
San Diego, CA), and strained through a 70 m nylon filters (BD Biosciences, San Jose, 
CA). Red blood cells were lysed with ACK buffer according to manufacturer’s 
suggestions (Life Technologies, Grand Island, NY). Samples were fixed and 
permeabilized using BD Pharmigen Mouse FoxP3 buffer set (BD Biosciences, San Jose, 
CA). LSRII SORP flow cytometer (BD Biosciences, San Jose, CA) was used to analyze 
the following tumor-infiltrating cell subsets: CD8+, CD8+E7+, CD8+E7+GrzB+, CD4+Foxp3- 
(non-Treg), and CD4+Foxp3+ (Treg) cells within live CD3+CD45+ population.   
The following fluorophore conjugated antibodies purchased from BD Biosciences (San 
Jose, CA) or eBioscience (San Diego, CA) were used for flow cytometry assay: CD45-
PE, CD3-PE-CF594 or V450, CD8-V450 or APC, CD4-FITC, FoxP3-APC or PE-CF594, 
Granzyme B-APC. The FITC-conjugated dextramers specific to E749–57 peptide was 
purchased from Immudex (Fairfax, VA). Live cells were identified by fixable near infra-
red Live/Dead viability staining as suggested by manufacturer (Life Technologies, Grand 
Island, NY). Acquired data were analyzed using FlowJo software, version 10 (TreeStar, 
Ashland, OR). 
The absolute numbers of tumor-infiltrating cells were standardized per 106 of total tumor 
cells. The fold change of tumor infiltrating immune cells was presented as fold change 
over the non-treated group. 
 
Evaluation of IDO activity  
The IDO enzymatic activity in tumor homogenates was assessed using high-
performance liquid chromatography (HPLC) techniques as described earlier [48]. Briefly, 
a concentration of kynurenine (tryptophan catabolite) was measured before and after 2 
hrs of addition of exogenous L-tryptophan substrate solution into tumor homogenates. 
Tumors were harvested from control and treated mice. The treatment schedule and 
tumor harvest were the same as for the assessment of immunology response. 
 
Statistical analysis 
All statistical parameters (average values, SD, significant differences between groups) 
were calculated using GraphPad Prism software. Statistical significance between groups 
was determined by One-way ANOVA with a Tukey multiple comparison post-test (P < 
0.05 was considered statistically significant).  
 
Results  
Indoximod enhances agonistic effect of anti-OX40 to eradicate tumors 
It is known that engagement of OX40 on T cells with its ligand or agonist antibody leads 
to increased INF expression in the periphery and within the tumor microenvironment 
[16, 17].  INF induces IDO, which in turn produces a range of immune inhibitory effects 
within the tumor microenvironment [49, 50]. Accordingly, we tested whether inhibiting the 
IDO pathway would enhance the therapeutic effect of anti-OX40.  We tested this 
hypothesis in the TC-1 tumor model that lacks IDO expression to identify the effects of 
the combination specifically on the immune component of the tumor microenvironment 
rather than on the tumor cells. We first evaluated tumor growth and survival of animals 
after treatment of TC-1 tumor-bearing mice with vaccine, anti-OX40 agonist Ab and 
indoximod. TC-1 tumor cells were implanted on day 0 and treatment was initiated when 
tumors reached 4-5mm in diameter. Tumor-bearing mice were treated weekly with an E7 
peptide vaccine to generate an effector T-cell response against the tumor. Anti-OX40 
agonist was administered twice a week and indoximod was provided in drinking water 
throughout the experiment as depicted in Fig. 1A, and tumor growth and survival were 
monitored.  
We found that although none of the single-agent treatments affects the tumor growth, 
vaccine/anti-OX40 leads to slower tumor progression and complete tumor regression in 
20% of the mice when added to the vaccine (Fig. 1B). The addition of indoximod to this 
treatment significantly enhanced therapeutic efficacy resulting in a complete eradication 
of established tumors in 60% of the mice. In addition, enhanced therapeutic efficacy 
after treatment with vaccine and anti-OX40 was seen early in the treatment (Fig. 1C; day 
26 representing the last day when all mice are surviving in all control groups). However, 
incorporation of indoximod into this treatment improved the long term therapeutic 
outcome as shown at day 40 (Fig. 1D). Moreover, compared to the single treatments, 
vaccine/anti-OX40 led to prolonged survival and addition of indoximod to this treatment 
resulted in a sustained response beyond 65 days (Fig. 1B, E). These data demonstrate 
that IDO inhibition with indoximod significantly enhances the effect of OX40 agonist 
antibody.  
 
Combination of anti-OX40 with indoximod results in significant increase of CD8+ T 
cell to Treg ratio 
To dissect the immune mechanisms leading to the enhanced therapeutic efficacy of 
vaccine/anti-OX40/indoximod treatment, we tested the effect of the combination on the 
tumor-infiltrating T cells. Animals were treated as mentioned above; six days after the 
second vaccination, mice were sacrificed and tumors were harvested for evaluation of 
tumor-infiltrating T-cell subsets by flow cytometry.  
Neither the single agent treatments nor the vaccine/anti-OX40 combination significantly 
affected CD4+FoxP3- T-cell tumor infiltration compared with either agent alone. However, 
we found that the addition of indoximod to vaccine/anti-OX40 led to a significant 
increase in tumor-infiltrating CD4+FoxP3- (non-Treg CD4+ T cells) (Fig. 2A).  None of the 
treatments significantly affected the numbers of tumor-infiltrating Tregs (Fig. 2B). 
Although the percentage of tumor-infiltrating Treg cells within the total CD4+ T-cell 
population was decreased in the vaccine/anti-OX40 group (due to increase of 
CD4+FoxP3- T cells), this reduction was more significant when indoximod was added to 
the treatment (Fig. 2C).  
Next, we explored the effect of the addition of indoximod to anti-OX40 on tumor-
infiltrating CD8+ T cells. We found that treatment with vaccine/anti-OX40 significantly 
increased the number of CD8+ T cells infiltrating the tumor compared to mice from 
control groups (Fig. 3A).  Although addition of indoximod to vaccine/anti-OX40 resulted 
in better antitumor response, no significant differences were found in the numbers of 
tumor-infiltrating CD8+ T cells over the vaccine/anti-OX40 group (Fig. 3A). Both groups 
showed a significant increase in CD8+/Treg ratio when compared to control groups (Fig. 
3B). 
These data demonstrate that the enhanced antitumor efficacy caused by inhibition of 
IDO is not facilitated by the increase in CD8+ T cell number, suggesting the existence of 
other mechanisms driving the therapeutic efficacy of the combination treatment. 
 
Addition of indoximod to anti-OX40 treatment increases antigen-specific 
functional CD8+ T cells 
We have demonstrated that the addition of indoximod to vaccine/anti-OX40 
immunotherapy did not affect the total number of tumor infiltrating CD8+ T cells or the 
CD8+/Treg ratio, despite the fact that addition of indoximod improved therapeutic efficacy 
of anti-OX40.  
Therefore, to understand the reasons for improved therapeutic outcome when indoximod 
is added to vaccine/anti-OX40, we first confirmed the efficacy of indoximod for the IDO 
enzymatic activity within tumor homogenates by measuring the levels of kynurenine 
catabolites. As expected, we detected no differences of kynurenine catabolites produced 
by tumor homogenates after addition of exogenous tryptophan in untreated mice and 
animals treated with vaccine alone or vaccine/anti-OX40 compared to non-treated mice 
(Fig. 4A). Moreover, there was no difference in IDO activity in mice treated with anti-
OX40/indoximod and vaccine/indoximod. However, mice treated with vaccine/anti-
OX40/indoximod had significantly decreased IDO activity (P < 0.05) compared to non-
treated (Fig. 4A).  
Next we tested the antigen-specificity and functionality of tumor-infiltrating CD8+ T cells, 
which could also be responsible for the differences in therapeutic efficacy between 
vaccine/anti-OX40 and vaccine/anti-OX40/indoximod treatments.  
The specificity and functionality of tumor-infiltrating CD8+ T cells were evaluated from 
mice treated with vaccine, vaccine/anti-OX40, vaccine/indoximod, or vaccine/anti-
OX40/indoximod as described above. Although the addition of indoximod to anti-
OX40/vaccine was unable to increase the total number of CD8+ T cells in the tumor 
microenvironment compared to vaccine/OX40 group (Fig. 3A), incorporation of 
indoximod into the treatment resulted in a significantly higher number of tumor-infiltrating 
antigen (E7)-specific CD8+ T cells compared to all other groups (Fig. 4B). Granzyme B 
(GrzB) expression was used to characterize the functionality of these CD8+ T cells. We 
demonstrated that the addition of indoximod to vaccine/anti-OX40 also led to a 
significant increase in the number of tumor-infiltrating CD8+GrzB+ antigen-specific T cells 
compared to all other groups (Fig. 4C).  
These data demonstrate that providing indoximod simultaneously with vaccine/anti-
OX40 not only leads to decreased IDO activity in tumor but also increases numbers of 
functional antigen-specific CD8+ T cells, which might explain the differences in 
therapeutic efficacy observed between the treatment groups. 
Thus, we show that although the addition of anti-OX40 to vaccine treatment enhances 
the numbers of CD8+ T cells in tumors (“quantity”), addition of indoximod improves the 
“quality” of these CD8+ T cells (enhanced antigen-specificity and functionality).   
 
Discussion  
Here we tested the agonist anti-OX40 in combination with the IDO pathway inhibitor, 
indoximod in the context of cancer vaccine. We showed that anti-OX40 agonist can 
enhance the effect of vaccine treatment resulting in slower tumor progression and 
complete regression of established tumors in 20% of treated mice. We hypothesized that 
the addition of indoximod to anti-OX40 treatment can improve the overall therapeutic 
efficacy of vaccine treatment. We showed that combinational treatment with 
vaccine/anti-OX40/indoximod significantly enhanced antitumor efficacy and resulted in 
complete tumor eradication in 60% of mice. While evaluating immunologic mechanisms 
responsible for this potent therapeutic outcome, we found that an increase of tumor-
infiltrating CD8+ T cells for the combinational treatments is mediated by anti-OX40, since 
both vaccine/anti-OX40 and vaccine/anti-OX40/indoximod treatments had similar 
numbers of CD8+ T cells. Likewise, anti-OX40 was responsible for the increase in non-
Treg CD4+ T-cell infiltration into the tumor, thus resulting in decreased percentage of 
Treg cells within the tumor-infiltrating CD4+ T-cell population.  
We found no significant effect of anti-OX40 on the number of tumor infiltrating Tregs. 
This contrasts with results in the CT26 tumor model, where the same anti-OX40 clone 
resulted in Treg depletion within the tumor and led to enhanced therapeutic efficacy [51]. 
This could be attributed to the different immune profiles of the two tumor models.  
We found no differences in numbers of tumor-infiltrating CD8+ T cells or in CD8+/Treg 
ratio, a well-established criteria that correlates with cancer prognosis [45, 52], between 
vaccine/anti-OX40 and vaccine/anti-OX40/indoximod treatments, even though the 
therapeutic efficacy for these treatments was significantly different. To understand this 
phenomenon, we evaluated the specificity and functionality of tumor-infiltrating CD8+ T 
cells. We found that numbers of both E7-specific and Granzyme B+ functional antigen-
specific CD8+ T cells were elevated within the tumors of mice treated with vaccine/anti-
OX40/indoximod compared to other groups. This at least partially explains the 
differences in antitumor therapeutic efficacies between these two treatments. 
Considering that more than half of the human tumors are IDO- [46], we selected the TC-1 
tumor model for evaluation of indoximod-based immunotherapy. As these tumor cells (in 
culture and in vivo) do not express IDO, the observed effect elicited by indoximod would 
be due not to its direct effect on tumor cells but rather to its effect on immune 
suppressive cells within the tumor microenvironment. Under normal physiological 
conditions, IDO contributes to maintenance of immune tolerance [27]. The catabolic 
effect of IDO on tryptophan depletion and kynurenine accumulation leads to T-cell arrest 
or apoptosis [34-37]. In the tumor setting this phenomenon enhances tumor growth by 
hindering immune effector cell function [28, 33, 38]. We observed no differences in IDO 
activity between animals treated with vaccine or with vaccine/anti-OX40, whereas the 
addition of indoximod to vaccine/anti-OX40 decreased IDO activity compared to other 
groups. Thus, one possibility for increased specificity and functionality of tumor-
infiltrating CD8+ T cells from mice treated with indoximod in addition to vaccine/anti-
OX40 is the decrease in IDO enzymatic activity within the tumors of these mice.  
In conclusion, here we demonstrate the synergistic antitumor therapeutic effect of 
vaccine/anti-OX40/indoximod combination that leads to tumor regression, and explore 
the immune mechanisms responsible for that synergy. Dissecting the mechanisms for 
each compound within the combination shows that anti-OX40 is responsible for the 
overall increase in numbers, and indoximod for specificity and functionality of vaccine-
induced CD8+ T cells. We provide evidence that simultaneous targeting of the effector 
and suppressor arms of the immune system synergistically promotes tumor eradication. 
This translatable strategy may enhance the overall efficacy of cancer treatment.  
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Figure legends 
Figure 1. Combination of vaccine, anti-OX40 Ab and indoximod provides potent 
antitumor therapeutic efficacy. A. C57BL/6 mice (n = 5/group) were injected s.c. in the 
right flank with 7x104 TC-1 cells. Mice from appropriate groups were injected weekly with 
vaccine (s.c.) or PBS as a control into the right flank. Anti-OX40 was injected i.p. twice a 
week starting on Day 10 after tumor implantation throughout the experiment. Indoximod 
was provided in drinking water starting Day 10 throughout the experiment. Tumor sizes 
were measured every 3-4 days. B. Plots represent tumor volumes of individual mice for 
each treatment. Ratio on the plots shows number of mice with completely regressed 
tumors over total number of mice in the group. Average tumor volumes ± SD on days 26 
(C) and 40 (D).  E. Kaplan–Meier plot of the overall survival. Similar results were 
obtained from two independent experiments. *P < 0.05, ** P < 0.01. Experiment was 
repeated three times with similar results. 
 Figure 2. Vaccine/anti-OX40/indoximod treatments lead to an increase of non-Treg 
CD4+ T-cell infiltration into the tumor without affecting Treg cell number. C57BL/6 
mice (n = 4-5/group) were injected with 7x104 TC-1 cells and treated as for therapeutic 
studies, except on Day 23 mice were sacrificed, and tumor-infiltrating CD4+ T cells were 
analyzed in tumor homogenates by flow cytometry. The absolute numbers of tumor-
infiltrating cells were standardized per 106 of total tumor cells and presented as fold 
change over non-treated (NT) group for A. non-Treg CD4+ T cells (CD4+ FoxP3-), B. 
Treg cells (CD4+ FoxP3+ - no statistically significant differences were observed between 
any of the groups), or as a percentage of Tregs within CD4+ population (C).  * P < 0.05, 
** P < 0.01. Combined data from three independent experiments are shown.  
 
Figure 3. Both vaccine/anti-OX40 and vaccine/anti-OX40/indoximod treatments 
lead to an increase of CD8+ T-cell infiltration into the tumor and CD8+/Treg ratio.  
C57BL/6 mice (n = 4-5/group) were injected with 7x104 TC-1 cells and treated as for Fig. 
2, and tumor-infiltrating CD8+ T cells were analyzed in tumor homogenates by flow 
cytometry. The absolute numbers of tumor-infiltrating CD8+ T cells were standardized 
per 106 of total tumor cells and presented as fold change over non-treated (NT) group 
(A). B. The CD8+/Treg ratio was calculated from normalized numbers of CD8+ T cells 
and Tregs per 106 of total tumor cells. * P < 0.05, ** P < 0.01, *** P < 0.001. Combined 
data from three independent experiments are shown. 
 
Figure 4. Addition of indoximod to vaccine/anti-OX40 treatment leads to decrease 
in kynurenine and an increase of tumor-infiltrating E7-specific and E7+GrzB+ CD8+ 
T cells. A. Enzymatic activity of IDO was evaluated in tumor homogenates from control 
and treated mice. IDO activity was calculated as pmol kynurenine/hr/mg tissue. B and C. 
Tumor-bearing C57BL/6 mice (n = 5/group) were treated with vaccine alone, 
vaccine/anti-OX40, vaccine/indoximod or vaccine/anti-OX40/indoximod as described 
above. The absolute numbers of tumor-infiltrating E7 dextramer+ CD8+ T cells (B) and 
E7+GrzB+ CD8+ T cells (C) were standardized per 106 of total tumor cells and presented 
as mean values ±SD. *P < 0.05 compared to all other groups. Similar results were 
obtained from two independent experiments. 
 
 




